Testing for both sST2 and galectin-3 are considered class II recommendations for risk prediction in heart failure from the American College of Cardiology, American Heart Association, and Heart Failure Society of America Heart Failure guidelines [14,21], but are not included in ASCO or NCCN guidelines. This evidence concerns the gene LGALS3 and heart failure.